Avelumab initially received regulatory approval for patients with metastatic urothelial carcinoma in the post-platinum chemotherapy setting based on an objective response rate of 16.5%.1 In the post-platinum chemotherapy setting, both nivolumab and pembrolizumab also currently retain their regulatory approval status. However, the situation where avelumab has the strongest data is in the maintenance-switch setting. I initially discussed that topic in a Urotoday Clinical Trials Portal article almost 4 years ago.2 Of course, everything discussed in that article has been completed, and all highlighted trials were positive.